NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $351,000 | +25.8% | 18,000 | +15.5% | 0.01% | 0.0% |
| Q4 2020 | $279,000 | +16.2% | 15,578 | +9.8% | 0.01% | -25.0% |
| Q3 2020 | $240,000 | -52.3% | 14,194 | -36.7% | 0.01% | -55.6% |
| Q2 2020 | $503,000 | -14.2% | 22,436 | +32.7% | 0.02% | -5.3% |
| Q2 2019 | $586,000 | -18.9% | 16,911 | -21.4% | 0.02% | -45.7% |
| Q1 2019 | $723,000 | -6.0% | 21,507 | -8.1% | 0.04% | -2.8% |
| Q4 2018 | $769,000 | -52.8% | 23,407 | -12.4% | 0.04% | -41.0% |
| Q3 2018 | $1,630,000 | -75.3% | 26,732 | +34.4% | 0.06% | -87.2% |
| Q2 2018 | $6,601,000 | – | 19,892 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |